Qiagen N.V. $QGEN Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC decreased its position in shares of Qiagen N.V. (NYSE:QGEN) by 24.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,177 shares of the company’s stock after selling 36,110 shares during the period. Segall Bryant & Hamill LLC’s holdings in Qiagen were worth $4,452,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new stake in shares of Qiagen during the first quarter valued at about $239,000. Prudential Financial Inc. lifted its stake in shares of Qiagen by 74.9% in the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock worth $426,000 after acquiring an additional 3,799 shares in the last quarter. Invesco Ltd. boosted its holdings in Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after purchasing an additional 556,387 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Qiagen by 226.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after purchasing an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in Qiagen during the 2nd quarter valued at approximately $3,639,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

QGEN has been the topic of a number of recent analyst reports. Barclays set a $38.00 target price on Qiagen and gave the company an “equal weight” rating in a research report on Wednesday, April 29th. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Citigroup reaffirmed a “hold” rating on shares of Qiagen in a report on Monday, May 18th. Weiss Ratings lowered shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $43.00 target price on shares of Qiagen in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Qiagen has an average rating of “Hold” and a consensus price target of $43.34.

Qiagen Stock Up 2.1%

Qiagen stock opened at $42.27 on Tuesday. The company has a 50-day simple moving average of $38.96 and a 200-day simple moving average of $41.81. The firm has a market capitalization of $8.71 billion, a P/E ratio of 22.08, a P/E/G ratio of 4.13 and a beta of 0.63. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. Qiagen N.V. has a one year low of $32.53 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $492.32 million for the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same period last year, the firm posted $0.56 EPS. As a group, equities analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This represents a dividend yield of 90.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s dividend payout ratio is presently 18.32%.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.